Dr. Alexander Asanov
CEO, TIRF Labs, Inc.,
517 Willard Woods Dr., Wendell, NC 27591
alex.asanov@TIRF-Labs.com
April 24, 2025
Open letter to:
Elon Musk
CEO, Tesla, SpaceX, and X
Subject: MAHA: Prevent new pandemics – support non-profit project i-Diagnostics
Dear Mr. Musk,
Colonization of Mars, becoming an interstellar civilization, as well as survival of humanity on Earth depend on our capability of preventing pandemics. It is already feasible with two platform technologies – TIRF Analytix and i-Diagnostics. The former will create a global network of scientists and healthcare professionals, and the latter will become a mega-diagnostics gadget for home-use, available for all. I am writing to you because you have launched several endeavors that fantastically benefited humanity. I inquire about your support for a project of equal scale, which pursues the goal of creating a global (and maybe interstellar in the future) infrastructure for preventing new pandemics.
In 2014-2019 many experts foresaw an RNA-virus pandemic coming. However, before COVID-19, TIRF Labs didn’t have resources for massive manufacturing. Currently, we are again at the verge of a new pandemic. We have the necessary technologies and inquire for your support, the U.S. Government grants, and philanthropic donations to build the infrastructure for global biological security.
We believe that non-profit status is important for such a project to ensure prosocial motivation, independence, and golden standards of science, unaffected by commercial interests. We declined the for-profit route and pledged to make TIRF Analytix and i-Diagnostics genuine Open Source platforms available to everyone.
This project represents an opportunity for The Giving Pledge, other philanthropists, and everyone who is willing to return back to society. Thousands of research groups worldwide have expressed their intentions to develop applications in their areas of expertise using TIRF Analytix and create a multitude of cartridges and applications for i-Diagnostics gadgets. Coordinated global network of users will build the infrastructure for localizing the outbreaks and preventing the emergence of pandemics.
Briefly, our technologies use the phenomenon of Total Internal Reflection Fluorescence (TIRF), which provides an extremely thin layer of excitation light ~100 nm, thus removing the background interference, maximizing the sensitivity and minimizing false-positive and false-negative responses. TIRF Analytix instruments are capable of detecting single molecules. They are competing with Zeiss, Nikon, Leica, and Olympus. However, there is no competition and no analogy to our handheld i-Diagnostics devices. Our team has excelled with Phase 1 of this project and is fully ready to move to Phase 2 – make TIRF Analytix available for research groups and i-Diagnostics – for all. Please refer to tirf-labs.com/i-diagnostics/ for details.
The following features place i-Diagnostics into uniquely advantageous position with respect to alternative technologies:
- Ultimate sensitivity down to single molecules – the ability to detect early stages of diseases
- Superior confidence – minimal rate of false-positive and false-negative responses
- Fast results – providing test results within 5 minutes – simplifying the logistics
- Minimal requirement to sample preparation allows for home-use and point-of-care diagnosing
- Mega-diagnostics: single TIRF microchip can analyze over 200 different biomarkers
- Simultaneous detection of DNA, RNA, protein, metabolite biomarkers, and chemical agents
- Chemical-biological analyzer: single microchip enables detection of multiple chemical and biological agents
With Phase 1 already being completed, TIRF Labs is looking to raise 2 million USD to start Phase 2 and 75 million to create the global infrastructure. We plan to establish a North Carolina Research Triangle Park-based center for i-Diagnostics, which will coordinate global efforts of preventing future pandemics and emerging precision medicine for all.
We are delighted to invite you to become a part of this opportunity, which can MAHA – Make America Healthy Again, revolutionize the current state of medicine, improve the quality and reduce the cost of healthcare by billions of dollars. Let’s MAHA and change the future of healthcare to be always a step ahead of any disease.
With highest regards,
Alexander Asanov, Ph.D.
CEO, TIRF Labs, Inc.
Research Triangle Park, NC
Info@tirf-labs.com
Encl: The project is outlined in the brochure and described at URL: www.tirf-labs.com/i-diagnostics/
Dr. Alexander Asanov
CEO, TIRF Labs, Inc.,
517 Willard Woods Dr., Wendell, NC 27591
alex.asanov@TIRF-Labs.com
April 26, 2025
Open letter to:
Robert F. Kennedy Jr.
US Secretary of Health and Human Services
200 Independence Avenue, S.W.
Washington, D.C. 877-696-6775;
Subject: MAHA: prevent new pandemics – support non-profit project i-Diagnostics.
Dear Secretary Kennedy:
I am inquiring about an in-person meeting with you to discuss several MAHA-related topics, including i-Diagnostics project, which goal is to prevent new pandemics and minimize the damage from existing diseases. It is feasible with two platform technologies - TIRF Analytix and i-Diagnostics. The former will create a global network of scientists and healthcare professionals, and the latter will become a mega-diagnostics gadget for home use, available for all.
In 2014-2019 many experts foresaw an RNA-virus pandemic coming. However, before COVID-19, TIRF Labs didn’t have resources for massive manufacturing. Currently, we are again at the verge of a new pandemic. We have the necessary technologies and inquire for your support, the U.S. Government grants, and philanthropic donations to build the infrastructure for global biological security.
We believe that non-profit status is important for such a project to ensure prosocial motivation, independence, and golden scientific standards, unaffected by commercial interest. We declined the for-profit route and pledged to make TIRF Analytix and i-Diagnostics genuine Open Source platforms available to everyone.
This project represents an excellent opportunity for The Giving Pledge, other philanthropists, and everyone who is willing to return back to society. Thousands of research groups worldwide have expressed their intentions to develop applications in their areas of expertise using TIRF Analytix and create a multitude of cartridges for i-Diagnostics gadgets. Coordinated global network of users will build the infrastructure for localizing the outbreaks and preventing the emergence of pandemics.
Briefly, our technologies use the phenomenon of Total Internal Reflection Fluorescence (TIRF), which provides an extremely thin layer of excitation light ~100 nm, thus removing the background interference, maximizing the sensitivity and minimizing false-positive and false-negative responses. TIRF Analytix instruments are capable of detecting single molecules. They are competing with Zeiss, Nikon, Leica, and Olympus. However, there is no competition and no analogy to our handheld i-Diagnostics devices. Our team has excelled with Phase 1 of this project and is fully ready to move to Phase 2 - make TIRF Analytix available for research groups and i-Diagnostics - for all. Please refer to tirf-labs.com/i-diagnostics/ for details.
The following features place i-Diagnostics into advantageous position with respect to alternative technologies:
• Ultimate sensitivity down to single molecules – the ability to detect early stages of diseases
• Superior confidence – minimal rate of false-positive and false-negative responses
• Fast results – providing test results within 5 minutes – simplifying the logistics
• Minimal requirement to sample preparation allows for home-use and point-of-care diagnosing
• Mega-diagnostics: single TIRF microchip can analyze over 200 different biomarkers
• Simultaneous detection of DNA, RNA, protein, metabolite biomarkers, and chemical agents
With Phase 1 already being completed, TIRF Labs is looking to raise 2 million USD to start Phase 2 and 75 million to create the global infrastructure. We plan to create a North-Carolina-Research-Triangle-Park-based center for i-Diagnostics, which will coordinate global efforts on preventing future pandemics and precision medicine for all. We are delighted to inquire about your support for the project, which can become an essential part of MAHA – Make America Healthy Again efforts, revolutionize the current state of medicine, improve the quality and reduce the cost of healthcare by billions of dollars and be always a step ahead of any disease.
With highest regards,
Alexander Asanov, Ph.D., CEO, TIRF Labs, Inc.
April 26, 2025
Open letter to:
Jayanta Bhattacharya, M.D., Ph.D.
Director of the National Institutes of Health
National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892 ph: 301-496-4000
Subject: MAHA: prevent new pandemics – support non-profit project i-Diagnostics.
Dear Dr. Bhattacharya,
In 2020 you co-authored and I co-signed the Great Barrington Declaration. In 2025 you became the Director of NIH, and I am inquiring your support for non-profit project i-Diagnostics, which goal is to prevent new pandemics and minimize the damage from existing diseases. It is feasible with two platform technologies - TIRF Analytix and i-Diagnostics. The former will create a global network of scientists and healthcare professionals, and the latter become a mega-diagnostics gadget for home-use, available for all.
Following 9/11 and the anthrax letter attacks, NIH and DHS HSARPA granted me $4.3M in BAA and SBIR awards to develop molecular diagnostics for CBRNE security. Our team of scientists and engineers exceeded the expectations for BAA and SBIR awards – we not only invented but also manufactured an array of instruments – TIRF Analytix for laboratory settings and handheld gadget i-Diagnostics for first-responders and home-use applications.
In 2014-2019 many experts foresaw an RNA-virus pandemic coming. However, TIRF Labs didn’t receive resources for i-Diagnostics manufacturing, because US Government agencies became affected by commercial interests. Nevertheless, just a few research groups worldwide that acquired our TIRF Analytix instruments discovered Ivermectin, HCQ, Fenofibrate and other off-label FDA-approved drugs for COVID prophylactics and treatment.
Currently, we are again at the verge of a new pandemic. We have the necessary technologies and inquire for your support, the U.S. Government grants, and philanthropic donations to build the infrastructure for global biological security. Because commercial interests prevail in many NIH study sections, I inquire for your independent reviewing and making decision on NIH funding of the non-profit i-Diagnostics project. To the best of my knowledge, there is no analogy and no competition to i-Diagnostics.
We believe that non-profit status is important for such a project to ensure prosocial motivation, independence, and golden scientific standards, unaffected by commercial interest. We declined the for-profit route and pledged to make TIRF Analytix and i-Diagnostics genuine Open Source platforms available to everyone. Thousands of research groups worldwide have expressed their interest to develop applications in their areas of expertise using TIRF Analytix and create a multitude of cartridges for i-Diagnostics gadgets. Coordinated global network of users will build the infrastructure for localizing the outbreaks and preventing the emergence of pandemics.
Briefly, our technologies use the phenomenon of Total Internal Reflection Fluorescence (TIRF), which provides an extremely thin layer of excitation light ~100 nm, thus removing the background interference, maximizing the sensitivity and minimizing false-positive and false-negative responses. TIRF Analytix instruments are capable of detecting single molecules. They are competing with Zeiss, Nikon, Leica, and Olympus. However, there is no competition and no analogy to our handheld i-Diagnostics devices. Our team has excelled with Phase 1 of this project and is fully ready to move to Phase 2 - make TIRF Analytix available for research groups and i-Diagnostics - for all. Please refer to tirf-labs.com/i-diagnostics/ for details.
The following features place i-Diagnostics into advantageous position with respect to alternative technologies:
• Ultimate sensitivity down to single molecules – the ability to detect early stages of diseases
• Superior confidence – minimal rate of false-positive and false-negative responses
• Fast results – providing test results within 5 minutes – simplifying the logistics
• Minimal requirement to sample preparation allows for home-use and point-of-care diagnosing
• Mega-diagnostics: single TIRF microchip can analyze over 200 different biomarkers
• Simultaneous detection of DNA, RNA, protein, metabolite biomarkers, and chemical agents
With Phase 1 already being completed, TIRF Labs is looking to raise 2 million USD to start Phase 2 and 75 million to create the global infrastructure. We plan to create a North-Carolina-Research-Triangle-Park-based center for i-Diagnostics, which will coordinate global efforts on preventing future pandemics and precision medicine for all. We are delighted to inquire about NIH support for the project, which can become an essential part of MAHA – Make America Healthy Again efforts, revolutionize the current state of medicine, improve the quality and reduce the cost of healthcare by billions of dollars and be always a step ahead of any disease.
With highest regards,
Alexander Asanov, Ph.D.
CEO, TIRF Labs, Inc.